Historical record - last NADAC effective date: 2/22/2023
Product Information
CONTRAVE ER 8-90 MG TABLET is a brand product labeled by Nalpropion Pharmaceuticals LLC, priced at $4.9810 per EA under NDC 51267089099. Its NADAC has been published 340 times since Mar 29, 2017.
FDA first approved this application on Sep 10, 2014.
Strength
90; 8 mg/1; mg/1
Manufacturer
Nalpropion Pharmaceuticals LLCNDC
51267089099
Classification
Brand
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
2/22/2023
Active Ingredients
BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA200063FDA Approved
9/10/2014
On Market Since
10/22/2014
Pharmacological Classes
Price Statistics
The NADAC for CONTRAVE ER 8-90 MG TABLET has been published 340 times since Mar 29, 2017, and over the history we have for it it has risen 181.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.9810 per EA |
|---|---|
| All-time high | $4.9877 (Feb 15, 2023) |
| All-time low | $1.7704 (Mar 29, 2017) |
| Median price | $2.2293 |
| Average price | $2.8714 |
| Largest weekly change | +105.9% (Mar 9, 2022) |
| Weeks tracked | 340 |
| Tracking since | Mar 29, 2017 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
+105.7%
All
+181.3%
Last surveyed Sep 27, 2023 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the naltrexone hydrochloride and bupropion hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Nalpropion Pharmaceuticals LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
naltrexone hydrochloride and bupropion hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminoketone class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CONTRAVE ER 8-90 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for CONTRAVE ER 8-90 MG TABLET, manufactured by Nalpropion Pharmaceuticals LLC, is $4.9810 per EA (NDC 51267089099), effective Sep 27, 2023.
How has the price of CONTRAVE ER 8-90 MG TABLET changed over time?
Over the history we have for it, the NADAC for CONTRAVE ER 8-90 MG TABLET has risen 181.3%. It has been tracked across 340 weekly CMS publications since Mar 29, 2017.
What are the highest and lowest recorded NADAC prices for CONTRAVE ER 8-90 MG TABLET?
Since Mar 29, 2017, the NADAC for CONTRAVE ER 8-90 MG TABLET has ranged from a low of $1.7704 (Mar 29, 2017) to a high of $4.9877 (Feb 15, 2023), with a median of $2.2293 per EA.
Are there cheaper alternatives to CONTRAVE ER 8-90 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of CONTRAVE ER 8-90 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CONTRAVE ER 8-90 MG TABLET?
CONTRAVE ER 8-90 MG TABLET (NDC 51267089099) is labeled by Nalpropion Pharmaceuticals LLC, and CMS classifies it as a brand product.